United States Patent And Trademark Office Has Allowed U.S. Patent Application No. 17/496,470 Related To Treating Agitation In Patients With Alzheimer's Disease Using BioXcel Therapeutics' 60 mcg Oromucosal (Dexmedetomidine) In Water-soluble Dosage Form
Portfolio Pulse from Benzinga Newsdesk
The U.S. Patent and Trademark Office has allowed a patent application for BioXcel Therapeutics' BXCL501, a treatment for agitation in Alzheimer's patients. The patent covers various formulations and is expected to expire on Dec. 29, 2037, with potential adjustments.
February 05, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioXcel Therapeutics' BXCL501 receives patent approval for treating Alzheimer's agitation, with an expiration in 2037.
The approval of the patent for BXCL501 by the USPTO is a significant milestone for BioXcel Therapeutics. It not only strengthens the company's intellectual property portfolio but also enhances its competitive position in the market for Alzheimer's treatment. The long-term patent protection until 2037 provides a substantial period for BioXcel to capitalize on BXCL501, potentially leading to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100